01557nas a2200241   4500000000100000008004100001260001200042653001200054653003000066653002100096653002300117100001300140700001500153700001300168700001200181700001400193245007800207856009200285300000800377490000700385520090900392022001401301       2025                            d  c01/202510aLeprosy10aErythema Nodosum Leprosum10aLeprosy reaction10aBiological Therapy1 aGomide L1 aBrufatto J1 aKucarz T1 aVelho P1 aFrança A00aManaging leprosy reactions with secukinumab: Insights from a case series.  uhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12479038/pdf/1678-9849-rsbmt-58-e0118-2025.pdf  a1-50 v583 a<p><strong>Background</strong></p>

<p>Erythema nodosum leprosum (ENL) is an immunological inflammatory reaction requiring precise management. Recalcitrant cases, their refractoriness to conventional therapy, and the adverse effects of standard treatments underline the need to explore alternative therapeutic options.</p>

<p><strong>Methods</strong></p>

<p>We conducted a retrospective study of five patients treated with secukinumab between January 2023 and January 2025.</p>

<p><strong>Results</strong></p>

<p>Patients showed clinical improvement with a reduced ENL frequency, neuritis relief, and corticosteroid sparing.</p>

<p><strong>Conclusions</strong></p>

<p>Secukinumab appears to be a promising corticosteroid-sparing option for ENL, with a favorable safety profile. Further studies are required to confirm the efficacy and long-term safety of this treatment regimen.</p>
  a1678-9849